WHWK · Insider Trading

Whitehawk Therapeutics, Inc. Common Stock

Every open-market purchase and sale reported by WHWK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.

Form 4 Filings
50
most recent
Open-Market Buys
0
code P
Sales
5
code S
Reporting Insiders
6
current holders
WHWK — Recent Form 4 Transactions (latest 2026-09-18)
FiledInsiderRole TypeSharesValue
2026-09-18 David James Lennon CHIEF EXECUTIVE OFFICER A +387,914 deriv. —
2026-09-18 Scott M. Giacobello CHIEF FINANCIAL OFFICER A +236,952 deriv. —
2026-09-18 Bryan Ball See remarks A +183,266 deriv. —
2026-09-18 Margaret Dugan Chief Medical Officer A +162,500 deriv. —
2026-09-18 David Dornan Chief Scientific Officer A +171,774 deriv. —
2026-09-15 Margaret Dugan Chief Medical Officer A +162,500 deriv. —
2026-09-15 Bryan Ball See remarks A +183,266 deriv. —
2026-09-15 Scott M. Giacobello CHIEF FINANCIAL OFFICER A +236,952 deriv. —
2026-09-15 David Dornan Chief Scientific Officer A +171,774 deriv. —
2026-09-15 David James Lennon CHIEF EXECUTIVE OFFICER A +387,914 deriv. —
2026-09-11 Vijay K Iyengar Director A +76,080 deriv. —
2026-07-30 Anupam Dalal Director A +1,275,510 +$5.00M
2026-06-15 Neil Desai Director A +38,040 deriv. —
2026-06-15 Richard E Maroun Director A +38,040 deriv. —
2026-06-15 Avoro Capital Advisors LLC Director A +38,040 deriv. —
2026-06-15 Mohammad Hirmand Director A +38,040 deriv. —
2026-06-15 Caley Castelein Director A +38,040 deriv. —
2026-06-15 Baiteng Zhao Director A +38,040 deriv. —
2026-06-15 Emma Reeve Director A +38,040 deriv. —
2026-05-18 Scott M. Giacobello CHIEF FINANCIAL OFFICER A +38,265 +$150.00K
2026-05-18 Bryan Ball See remarks A +51,020 +$200.00K
2026-05-18 David James Lennon CHIEF EXECUTIVE OFFICER A +51,021 +$200.00K
2026-05-18 Margaret Dugan Chief Medical Officer A +19,132 +$75.00K
2026-05-18 Caley Castelein Director A +255,102 +$1000.00K
2026-05-14 Avoro Capital Advisors LLC Director A +6,377,714 deriv. —
2026-04-17 Scott M. Giacobello CHIEF FINANCIAL OFFICER Sell −218,600 −$882.03K
2026-04-15 Bryan Ball See remarks Sell −118,849 −$427.86K
2026-04-13 Bryan Ball See remarks Sell −56,596 −$201.12K
2026-04-10 David James Lennon CHIEF EXECUTIVE OFFICER Sell −14,500 −$49.01K
2026-04-08 David James Lennon CHIEF EXECUTIVE OFFICER Sell −260,427 −$899.54K
2026-04-03 David Dornan Chief Scientific Officer A +282,340 deriv. —
2026-04-03 Margaret Dugan Chief Medical Officer A +283,157 deriv. —
2026-04-03 Scott M. Giacobello CHIEF FINANCIAL OFFICER M +473,902 —
2026-04-03 David James Lennon CHIEF EXECUTIVE OFFICER MIXED +748,970 −$93.47K
2026-04-03 Bryan Ball See remarks M +366,532 —
2026-03-10 Scott M. Giacobello CHIEF FINANCIAL OFFICER MIXED +4,156 −$8.59K
2026-03-10 Bryan Ball See remarks MIXED +3,166 −$6.07K
2026-03-10 David James Lennon CHIEF EXECUTIVE OFFICER MIXED +11,150 −$16.88K
2025-12-02 Margaret Dugan Chief Medical Officer A +705,309 deriv. —
2025-06-17 Neil Desai Director A +40,006 deriv. —
2025-06-17 Baiteng Zhao Director A +40,006 deriv. —
2025-06-16 Emma Reeve Director A +40,006 deriv. —
2025-06-16 Anupam Dalal Director A +40,006 deriv. —
2025-06-16 Richard E Maroun Director A +40,006 deriv. —
2025-06-16 Mohammad Hirmand Director A +40,006 deriv. —
2025-06-16 Caley Castelein Director A +40,006 deriv. —
2025-06-16 Avoro Capital Advisors LLC Director A +40,006 deriv. —
2025-04-03 Bryan Ball See remarks A +733,064 deriv. —
2025-04-03 Scott M. Giacobello CHIEF FINANCIAL OFFICER A +947,804 deriv. —
2025-04-03 David James Lennon CHIEF EXECUTIVE OFFICER A +1,551,656 deriv. —
WHWK — Current Insider Holders
InsiderRole Shares HeldValue
Anupam Dalal Director 4,687,042 $14.67M
Caley Castelein Director 2,440,794 $7.64M
David James Lennon CHIEF EXECUTIVE OFFICER 569,643 $1.78M
Bryan Ball See remarks 448,126 $1.40M
Scott M. Giacobello CHIEF FINANCIAL OFFICER 333,489 $1.04M
Margaret Dugan Chief Medical Officer 19,132 $59.88K
WHWK Insider Trading FAQ
Who are the insiders at WHWK?
6 officers, directors and 10%+ beneficial owners currently report holdings in WHWK via SEC Form 4.
Are WHWK insiders buying or selling?
Across the 50 most recent Form 4 filings for WHWK, 0 were open-market purchases (code P) and 5 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is WHWK insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent WHWK filing is dated 2026-09-18.
How to read Form 4 activity

Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.

Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.

Full filing history and per-insider positions are on the WHWK quote page; the site-wide leaderboard is on the insider transactions hub.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.